{
    "ticker": "MNDR",
    "name": "Madrigal Pharmaceuticals, Inc.",
    "description": "Madrigal Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company focused on the development of innovative therapies for the treatment of cardiovascular and metabolic diseases. Founded in 2008, Madrigal is committed to addressing significant unmet medical needs and improving the lives of patients through its robust pipeline of drug candidates. The company's lead product candidate, resmetirom, is a selective thyroid hormone receptor beta agonist that has shown promise in treating nonalcoholic steatohepatitis (NASH), a progressive liver disease associated with obesity and diabetes. Madrigal is also exploring other applications of its therapies in metabolic diseases and has several programs in early stages of development. With a strong emphasis on scientific research and clinical development, Madrigal is dedicated to advancing its drug candidates through rigorous trials to demonstrate their safety and efficacy. The company\u2019s mission is to provide transformative therapies that enhance the quality of life for patients worldwide, and it is actively engaged in collaborations and partnerships to accelerate its research efforts.",
    "industry": [
        "Biotechnology",
        "Pharmaceuticals"
    ],
    "headquarters": "Worcester, Massachusetts, USA",
    "founded": "2008",
    "website": "https://www.madrigalpharma.com",
    "ceo": "Paul Friedman",
    "social_media": {
        "twitter": "https://twitter.com/madrigalpharma",
        "linkedin": "https://www.linkedin.com/company/madrigal-pharmaceuticals/"
    },
    "investor_relations": "https://investors.madrigalpharma.com",
    "key_executives": [
        {
            "name": "Paul Friedman",
            "position": "CEO"
        },
        {
            "name": "J. Michael Haller",
            "position": "CFO"
        }
    ],
    "product_categories": [
        {
            "category": "Therapeutics",
            "products": [
                "Resmetirom"
            ]
        }
    ],
    "seo": {
        "meta_title": "Madrigal Pharmaceuticals, Inc. | Innovative Therapies for Metabolic Diseases",
        "meta_description": "Explore Madrigal Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company dedicated to developing innovative therapies for cardiovascular and metabolic diseases.",
        "keywords": [
            "Madrigal Pharmaceuticals",
            "Biotechnology",
            "Pharmaceuticals",
            "NASH",
            "Resmetirom"
        ]
    },
    "faq": [
        {
            "question": "What is Madrigal Pharmaceuticals known for?",
            "answer": "Madrigal Pharmaceuticals is known for its innovative therapies targeting metabolic diseases, particularly NASH."
        },
        {
            "question": "Who is the CEO of Madrigal Pharmaceuticals?",
            "answer": "Paul Friedman is the CEO of Madrigal Pharmaceuticals, Inc."
        },
        {
            "question": "Where is Madrigal Pharmaceuticals headquartered?",
            "answer": "Madrigal Pharmaceuticals is headquartered in Worcester, Massachusetts, USA."
        },
        {
            "question": "What is Madrigal's lead product candidate?",
            "answer": "Madrigal's lead product candidate is resmetirom, which is aimed at treating nonalcoholic steatohepatitis (NASH)."
        },
        {
            "question": "When was Madrigal Pharmaceuticals founded?",
            "answer": "Madrigal Pharmaceuticals was founded in 2008."
        }
    ],
    "competitors": [
        "VRTX",
        "NVO",
        "AMGN",
        "GILD"
    ],
    "related_stocks": [
        "MRNA",
        "REGN",
        "BMY",
        "PFE"
    ]
}